Comparison the Effect of Letrozole Versus Medroxy Progesterone Acetate on Premenopausal Patients With Endometrial Hyperplasia: An Randomized clinical trial

The assessing the effect of letrozole and medroxyprogesterone acetate on women with simple endometrial hyperplasia without atypia in reproductive age.
Material and Eighty patients of Abolfazle clinic in Bushehr with abnormal uterine bleeding and simple endometrial hyperplasia enrolled in this study. The patients were randomized in 2 groups: group A included 40 patients who received 10 mg medroxyprogesterone acetate for 10 days in each month during 3 months and group B included 40 patient that received 2.5 mg letrozole for 3 months. Serial transvaginal sonography and estradiol were checked basically and repeated after 3 months of treatment. Main outcome measures were endometrial thickness and estradiol level in serum.
In 2 groups A & B, there were no significant differences in the base variables. The level of estradiol in groups A and B before treatment was similar in the 2 groups. Endometrial thickness in groups A and B was not statistically significant. The difference between these 2 groups from the endometrial thickness reduction viewpoint, is not significant (P value = 0.445). The level of decline estradiol in serum in the groups A&B was significant,
Letrozole is an acceptable drug for treatment of simple endometrial hyperplasia especially in the patients who did not tolerate medroxyprogesterone.